EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer

Ryota Shibaki, Daichi Fujimoto iD, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Junya Fukuoka, Yuki Sato, Takashi Kijima iD, Hirotaka Matsumoto, Toshihide Yokoyama, Satoru Miura iD, Akito Hata und 8 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-007987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Ryota Shibaki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Ⅲ, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In small-cell lung cancer (SCLC), the tumor immune microenvironment (TIME) could be a promising biomarker for immunotherapy, but objectively evaluating TIME remains challenging. Hence, we aimed to develop a predictive biomarker of immunotherapy efficacy through a machine learning analysis of the TIME.

Methods

We conducted a biomarker analysis in a prospective study of patients with extensive-stage SCLC who received chemoimmunotherapy as the first-line treatment. We trained a model to predict 1-year progression-free survival (PFS) using pathological images (H&E, programmed cell death-ligand 1 (PD-L1), and double immunohistochemical assay (cluster of differentiation 8 (CD8) and forkhead box P3 (FoxP3)) and patient information. The primary outcome was the mean area under the curve (AUC) of machine learning models in predicting the 1-year PFS.

Results

We analyzed 100,544 patches of pathological images from 78 patients. The mean AUC values of patient information, pathological image, and combined models were 0.789 (range 0.571–0.982), 0.782 (range 0.750–0.911), and 0.868 (range 0.786–0.929), respectively. The PFS was longer in the high efficacy group than in the low efficacy group in all three models (patient information model, HR 0.468, 95% CI 0.287 to 0.762; pathological image model, HR 0.334, 95% CI 0.117 to 0.628; combined model, HR 0.353, 95% CI 0.195 to 0.637). The machine learning analysis of the TIME had better accuracy than the human count evaluations (AUC of human count, CD8-positive lymphocyte: 0.681, FoxP3-positive lymphocytes: 0.626, PD-L1 score: 0.567).

Conclusions

The spatial analysis of the TIME using machine learning predicted the immunotherapy efficacy in patients with SCLC, thus supporting its role as an immunotherapy biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaHumansProgression-Free SurvivalB7-H1 AntigenProspective StudiesBiomarkers, TumorImmunotherapyMachine LearningForkhead Transcription FactorsTumor Microenvironment

Stichwörter der Autor:innen

Computational BiologyImmune Checkpoint InhibitorsLung NeoplasmsTumor BiomarkersTumor Microenvironment

Substanzen

B7-H1 AntigenBiomarkers, TumorForkhead Transcription Factors

Autor:innen und Institutionen

  • Internal Medicine Ⅲ, Wakayama Medical University, Wakayama, Japan.
  • Internal Medicine Ⅲ, Wakayama Medical University, Wakayama, Japan daichi@wakayama-med.ac.jp.
  • ExaWizards Inc, Tokyo, Japan.
  • Department of pathology informatics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.
  • Department of Respiratory Medicine and Hematology, Hyogo Medical University, Hyogo, Japan.

ORCID-Profile: Daichi Fujimoto, Takashi Kijima, Satoru Miura

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Shibaki, R., Fujimoto, D., Nozawa, T., Sano, A., Kitamura, Y., Fukuoka, J., Sato, Y., Kijima, T., Matsumoto, H., Yokoyama, T., Miura, S., Hata, A., Tamiya, M., Taniguchi, Y., Sugisaka, J., Furuya, N., Tanaka, H., Yamamoto, N., Koh, Y., & Akamatsu, H. (2024). Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007987

Vancouver

Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, et al. Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-007987

BibTeX
@article{Shibaki2024,
  author = {Shibaki, Ryota and Fujimoto, Daichi and Nozawa, Tsukasa and Sano, Akira and Kitamura, Yuka and Fukuoka, Junya and Sato, Yuki and Kijima, Takashi and Matsumoto, Hirotaka and Yokoyama, Toshihide and Miura, Satoru and Hata, Akito and Tamiya, Motohiro and Taniguchi, Yoshihiko and Sugisaka, Jun and Furuya, Naoki and Tanaka, Hisashi and Yamamoto, Nobuyuki and Koh, Yasuhiro and Akamatsu, Hiroaki},
  title = {Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-007987}
}
Kostenlos starten →